Beta

Nkarta, inc.NKTX.US Overview

US StockHealthcare
(No presentation for NKTX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

NKTX AI Insights

NKTX Overall Performance

NKTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NKTX Recent Performance

-2.12%

Nkarta, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

NKTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check NKTX's Trend

NKTX Key Information

NKTX Valuation Metrics

NKTX Profile

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Price of NKTX

NKTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NKTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.46
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1000000.00
PB Ratio
0.67
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.46
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1000000.00
PB Ratio
0.67
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NKTX's latest earnings report released?

    The most recent financial report for Nkarta, inc. (NKTX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NKTX's short-term business performance and financial health. For the latest updates on NKTX's earnings releases, visit this page regularly.

  • How much debt does NKTX have?

    As of the end of the reporting period, Nkarta, inc. (NKTX) had total debt of 76.42M, with a debt ratio of 0.19. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NKTX have?

    At the end of the period, Nkarta, inc. (NKTX) held Total Cash and Cash Equivalents of 42.38M, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NKTX's EPS continuing to grow?

    According to the past four quarterly reports, Nkarta, inc. (NKTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.37. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NKTX?

    Nkarta, inc. (NKTX)'s Free Cash Flow (FCF) for the period is -22.21M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 14.11% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NKTX?

    The latest valuation data shows Nkarta, inc. (NKTX) has a Price-To-Earnings (PE) ratio of -1.46 and a Price/Earnings-To-Growth (PEG) ratio of -0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.